ADIPOQ and myeloid sarcoma: The Adpn/Lep ratio was significantly lower in individuals with MS (Without MS: 1.01 ± 1.24; With MS: 0.26 ± 0.24; p < 0.001) as can be seen in Figure 1C. From the subjects without the MS 26% and 48% had an Adpn/Lep ratio in the ≥0.5–<1.0 and <0.5 groups, respectively, while in individuals with the MS the percentages were 9% and 90%, respectively, for the same groups (p < 0.001).